Compare Skyworks Solutions Inc (SWKS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs BIO-TECHNE Corp — how do they compare? Skyworks Solutions Inc trades at $79.5 (market cap $12.55B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Skyworks Solutions Inc and BIO-TECHNE Corp are close in size by market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and BIO-TECHNE Corp for 63 Days on average.
| SWKS | TECH | |
|---|---|---|
Market Cap | $12.55B | $11.37B |
Volume | 9,218,443 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $91.45 | $72.61 |
52-Week Low | $52.50 | $43.31 |
Typical Hold Time | 50 Days | 63 Days |
Enterprise Value | $12.44B | $11.40B |
Dividend Yield | 4.13% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $83.43, up 0.88% with neutral technical signals. The stock shows declining revenue from $4.8B in 2023 to $4.1B in 2025 and contracting profit margins from 20.59% to 11.67% over the same period. Recent Q2 2026 earnings beat expectations at $1.08 EPS versus $1.03 expected. The pending Qorvo merger, expected to close in 2026 with $500M in synergies, represents a major strategic shift that could enhance scale and market positioning.
While analyst consensus remains bullish (60% buy ratings) with a $78.80 price target, near-term risks include execution challenges with the merger integration and ongoing revenue pressure. The current P/E of 43.23 appears elevated relative to earnings growth trends, suggesting investors should weigh merger benefits against fundamental deterioration.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
